The COVID-19 virus continues to evolve, and one of the newest variants attracting attention is the BA.3.2 subvariant, often referred to in media as the “Cicada” variant. This strain has been monitored since late 2024 and has recently reappeared in multiple regions during 2025 and 2026, leading to renewed public interest in its symptoms, transmission, and risk level.
This article explains what the BA.3.2 variant is, how it behaves, its most common symptoms, and what precautions are recommended based on current scientific understanding.
The BA.3.2 variant is a sublineage of the Omicron family of the SARS-CoV-2 virus, which causes COVID-19. It was first identified in South Africa in November 2024 and later detected in several other countries after a period of low circulation.
The nickname “Cicada” comes from its pattern of apparent disappearance followed by re-emergence, similar to cicadas that remain underground for long periods before returning. Media reports have used this term to describe its resurfacing and renewed spread across multiple regions.
Health authorities, including the World Health Organization, currently classify BA.3.2 as a variant under monitoring. This means it is being tracked for changes in spread and severity, but it is not currently categorized as a high-risk global threat.
One of the main reasons scientists are paying attention to BA.3.2 is its mutation profile. The variant contains a large number of spike protein mutations compared to earlier Omicron subvariants. These mutations may influence how easily the virus spreads and how the immune system recognizes it.
Researchers are particularly interested in whether these changes could allow partial immune escape. This means that people who have previously been vaccinated or infected may still get infected again, although protection against severe illness is expected to remain strong.
At present, there is no solid evidence suggesting that BA.3.2 leads to more severe disease compared to earlier Omicron strains.
The symptoms associated with BA.3.2 are very similar to those seen in earlier Omicron variants. This makes it difficult to identify the variant based on symptoms alone without laboratory testing.
Most reported cases include the following symptoms:
Some patients also report additional symptoms, including:
A notable observation from recent reports is that sore throat tends to appear earlier and may feel more intense compared to previous variants. This has been highlighted in several clinical observations and news summaries.
Although BA.3.2 is part of the Omicron lineage, there are a few differences that researchers are examining closely.
BA.3.2 contains a higher number of mutations in the spike protein compared to earlier Omicron strains. These mutations may slightly alter how the virus attaches to human cells and how it is recognized by antibodies.
Early studies suggest that immunity from vaccination or past infection may not fully prevent infection, although it still provides strong protection against severe illness and hospitalization.
The variant spreads primarily through respiratory droplets and close contact, similar to other COVID-19 variants. It appears to be highly transmissible, especially in indoor or poorly ventilated environments.
Current evidence does not show an increase in disease severity compared to previous Omicron variants. Hospitalization and mortality rates remain similar to earlier strains.
BA.3.2 spreads in the same ways as other respiratory viruses:
Because of its transmissibility, outbreaks can occur quickly in communities where immunity is lower or where protective measures are not followed.
While most infections are mild to moderate, certain groups are more vulnerable to complications:
These groups are advised to stay up to date with vaccinations and take additional precautions when community transmission is high.
BA.3.2 cannot be identified based on symptoms alone. Standard COVID-19 tests are used for detection:
Because symptoms overlap with flu and other respiratory infections, testing is important for accurate diagnosis.
Treatment approaches for BA.3.2 are similar to other COVID-19 variants.
Most individuals recover within one to two weeks, although fatigue may last longer in some cases.
Even though the pandemic phase has eased, prevention remains important.
Recommended measures include:
Vaccines may not completely prevent infection, but they continue to provide strong protection against severe illness and hospitalization.
At present, public health experts suggest caution rather than alarm. The BA.3.2 variant spreads efficiently, but current data does not indicate increased severity.
Key points include:
The situation continues to be monitored by global health organizations, and guidance may evolve as new data becomes available.
The BA.3.2 “Cicada” COVID variant highlights the ongoing evolution of SARS-CoV-2. While it has developed multiple mutations and is spreading across regions, current evidence suggests it behaves similarly to other Omicron subvariants.
Staying informed, maintaining good hygiene practices, and keeping vaccinations updated remain the most effective ways to reduce risk.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.